10074-G5: Precision c-Myc Inhibition in Modern Cancer Research

Executive Summary: 10074-G5 is a crystalline small-molecule inhibitor designed to disrupt c-Myc/Max dimerization, a process central to the oncogenic transcriptional activity of c-Myc (product information). The compound induces cell cycle arrest and apoptosis in c-Myc-driven cancer models, with measurable IC50 values in both Daudi and HL-60 cell lines. In vivo, 10074-G5 achieves significant tumor growth suppression without systemic toxicity. Its solubility profile and purity support diverse research workflows. APExBIO supplies this compound with comprehensive documentation for reproducibility in cancer research workflows.

Biological Rationale

c-Myc is a basic helix-loop-helix leucine zipper (bHLH-ZIP) transcription factor that regulates genes involved in cell cycle progression, metabolism, differentiation, and apoptosis. Aberrant activation and overexpression of c-Myc is implicated in the pathogenesis of numerous malignancies, including prostate, pancreatic, lung, breast, and colon cancers, as well as B-cell lymphomas and leukemias. Elevated c-Myc levels are typically associated with tumor aggressiveness and poor clinical prognosis (Molecular Oncology). Recent studies have underscored the relevance of c-Myc within the c-Myc/TERT/NFκB axis, particularly in aggressive esophageal adenocarcinoma, where c-Myc protein accumulation promotes epithelial-to-mesenchymal transition (EMT) and enhanced tumor cell motility (related article). Targeting c-Myc/Max dimerization therefore represents a promising strategy for mitigating transcriptional programs that drive malignancy.

Mechanism of Action of 10074-G5

10074-G5 acts as a selective, small-molecule inhibitor that binds to c-Myc and prevents its heterodimerization with Max, a partner protein essential for c-Myc's DNA-binding and transcriptional activity. This disruption impairs the expression of c-Myc target genes, resulting in cell cycle arrest and apoptosis in c-Myc-dependent cells. At a concentration of 10 μM, 10074-G5 effectively inhibits c-Myc/Max dimerization and reduces total c-Myc protein levels (APExBIO product page). The compound's specificity for c-Myc/Max is well-established and has minimal off-target effects in non-c-Myc-driven cellular contexts (benchmark review).

Evidence & Benchmarks

• 10074-G5 exhibits an IC50 of 15.6 ± 1.5 μM in Daudi cells and 13.5 ± 2.1 μM in HL-60 cells, measured via apoptosis and viability assays (product information).
• At 10 μM, 10074-G5 disrupts c-Myc/Max dimerization and reduces c-Myc protein levels in vitro (protocol guide).
• Intravenous administration of 20 mg/kg for 10 days in C.B-17 SCID mice bearing Daudi xenografts leads to significant tumor growth suppression without affecting animal body weight (product information).
• 10074-G5 is a crystalline solid with a molecular weight of 332.3 and chemical formula C18H12N4O3, ensuring batch-to-batch reproducibility (specifications).
• The compound is soluble at ≥37.9 mg/mL in DMSO and ≥3.53 mg/mL in ethanol, but is insoluble in water (APExBIO).
• Recent molecular oncology research confirms c-Myc's central role in cancer aggressiveness and validates the importance of its inhibition (Molecular Oncology).

This article extends the insights from 10074-G5: Benchmark c-Myc Inhibitor for Cancer Research by emphasizing new mechanistic findings and translational benchmarks relevant to apoptosis and cell cycle studies. For deep-dive protocol troubleshooting and comparative workflows, see Reliable c-Myc Inhibition for Cell-Based Assays. To understand the broader oncogenic context, consult miR-196a Drives EAC Aggressiveness via the c-Myc/TERT/NFκB Axis, which details upstream regulatory factors influencing c-Myc activity.

Applications, Limits & Misconceptions

10074-G5 is primarily used in cancer research for:

• Dissecting the function of c-Myc in oncogenic signaling cascades.
• Enabling apoptosis and cell cycle arrest assays in c-Myc-dependent cell lines.
• Evaluating tumor regression in xenograft models where c-Myc is a key driver.
• Screening for synergistic or antagonistic effects with other pathway inhibitors.

Its use is not recommended in cell types or models where c-Myc is not a primary oncogenic driver, or in systems that require aqueous solubility without organic solvents. 10074-G5 is not suited for chronic in vivo administration due to limited long-term stability of its solutions and potential for precipitation. The compound is not a pan-transcription factor inhibitor; its specificity for c-Myc/Max is a key advantage and limitation.

Common Pitfalls or Misconceptions

• Assumption of Pan-Cancer Efficacy: 10074-G5 efficacy is restricted to c-Myc-driven tumors and will not impact cancers lacking c-Myc dependency.
• Inappropriate Solvent Use: Attempting to dissolve 10074-G5 in water leads to precipitation and loss of activity; always use validated solvents such as DMSO.
• Overlooked Protein Degradation: Reduced c-Myc protein may be due to both dimerization inhibition and enhanced degradation; this distinction matters for mechanistic studies.
• Assuming Long-Term Stability: Solutions of 10074-G5 are not stable for extended storage; fresh preparation is recommended for each experiment.
• Misapplication in Non-c-Myc Contexts: The inhibitor has limited utility in non-c-Myc-driven diseases or pathways.

Workflow Integration & Parameters

Protocol Parameters

• Stock Preparation: Dissolve at ≥37.9 mg/mL in DMSO or ≥3.53 mg/mL in ethanol (ultrasonic assistance recommended). Avoid water as solvent.
• In Vitro Assays: Typical working concentrations range from 5–20 μM; use 10 μM to disrupt c-Myc/Max dimerization and assess protein levels after 24–48 hours.
• In Vivo Dosing: Administer intravenously at 20 mg/kg daily for 10 days in mouse xenograft models. Monitor animal weight to assess systemic toxicity.
• Storage: Store solid compound at -20°C. Use freshly prepared solutions; avoid long-term storage due to instability.
• Assay Readouts: Confirm c-Myc protein reduction by immunoblotting; assess apoptosis via annexin-V/PI staining or caspase activity assays.

For laboratory troubleshooting and data interpretation using 10074-G5, see this scenario-based guidance, which expands on practical challenges and solutions.

Conclusion & Outlook

10074-G5 is a benchmark small-molecule c-Myc inhibitor, enabling precise dissection of oncogenic pathways in cancer research. Its validated biochemical and cellular effects have made it a standard tool for apoptosis and tumor regression studies. Ongoing research continues to clarify the centrality of c-Myc in cancer aggressiveness and therapy resistance, as highlighted by recent findings on the MYC/TERT/NFκB axis in esophageal adenocarcinoma (Molecular Oncology). As specificity and reproducibility remain paramount, APExBIO's 10074-G5 (SKU C5722) stands out for its quality and documentation, supporting both fundamental and translational oncology workflows. Future studies will likely explore combination strategies, but the critical role of c-Myc inhibition in reversing malignant phenotypes is now firmly established.